Many patients with severe gastroparesis unfortunately do not achieve adequate relief from the previously outlined therapies. In such cases, consideration should be given to implantation of a ...

Vanda Pharmaceuticals (VNDA) issued a letter to FDA Commissioner highlighting what the company considers a faulty gastroparesis NDA review.

Current research into effective treatments for gastroparesis is focused on agonists of motilin, a peptide hormone that accelerates gastric emptying. McCallum and colleagues studied whether ...

This may cause persistent nausea and vomiting. The symptoms include constant nausea and vomiting. → Common treatment options → Questions to ask your doctor Gastroparesis is said to be caused by ...

And so, the lack of awareness among general practitioners about gastroparesis further complicates timely diagnosis, often ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review.

As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025. Gimoti remains only approved drug shown to reduce hospitalizations, emergency ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As ...